Life science tools market seen reaching $332B by 2035

Market Research Future projects the global life science tools market will grow from $175.5 billion in 2026 to $332 billion by 2035, driven by government biotech funding, lower sequencing costs and automation in labs. The outlook points to strong demand for sequencing, mass spectrometry and consumables across research, diagnostics and biomanufacturing.

Why it matters: - The life science tools market is shifting from a capital-equipment cycle to a recurring-revenue model tied to sequencing, consumables and software. - Falling sequencing costs and AI-driven automation are broadening adoption beyond large research centers into hospitals, diagnostic labs and decentralized testing sites. - Public funding remains a major demand driver, making the market less dependent on discretionary healthcare spending.

What happened: - Market Research Future projects the global life science tools market will rise from $175.50 billion in 2026 to $332.00 billion by 2035. - The forecast implies a 7.35% compound annual growth rate from 2026 to 2035. - The market base was estimated at $163.50 billion in 2025. - The report ties growth to government biotech funding packages and AI-driven lab automation. - A sample request is available here. - The full report is available here.

The details: - Public-sector investment is the biggest growth catalyst in the report. - A proposed $88 billion U.S. biotechnology allocation for 2025 is expected to support automated sequencing centers, biosafety-level-3 lab upgrades and biomanufacturing pilot facilities. - Horizon Europe’s Cluster 1-Health had disbursed EUR 8.2 billion through 2024 and has more funding scheduled through 2027. - The NIH continues annual appropriations above $47 billion. - Canada’s Genomics Canada initiative has committed CAD 1.2 billion through 2028. - France 2030 has allocated EUR 7 billion to health-innovation infrastructure. - Per-genome sequencing costs have fallen from about $600 in 2020 to under $200 by late 2024. - The report says that cost drop is moving next-generation sequencing into community oncology practices and neonatal screening programs. - Next-generation sequencing is the fastest-growing technology segment, with an 18.2% CAGR projected for 2026-2035. - Robotic liquid-handling systems and machine-learning quality-control tools are reducing sample-preparation errors by an estimated 35%-40% in high-throughput environments. - Major pharmaceutical companies have committed more than $4 billion collectively to automated discovery labs between 2023 and 2025. - By 2030, the report estimates 45% of new mass spectrometry and flow cytometry installations will include on-board machine-learning modules. - Those systems are expected to cut operator dependency and raise throughput by 25%-30%. - Instruments held a 46.5% revenue share in 2025. - Consumables generated $62.80 billion in 2025. - PCR and qPCR held a 24.2% share in 2025. - Genomic technology held a 35.4% share in 2025. - Proteomics technology is projected to grow at a 14.1% CAGR from 2026 to 2035. - Research laboratories held a 62.0% share in 2025. - Diagnostic laboratories are projected to grow at a 12.75% CAGR from 2026 to 2035. - North America held about 40.5% of the market in 2025. - The United States generated about 82.3% of North American revenue. - Europe was the second-largest region at $45.45 billion in 2025. - Asia-Pacific is the fastest-growing region, at an 11.75% CAGR from 2026 to 2035. - The Middle East and Africa is projected to grow at an 8.65% CAGR from 2026 to 2035. - South America reached $8.50 billion in 2025.

Between the lines: - The market is moderately concentrated, with the top five firms holding an estimated 45%-52% of global revenue. - The report estimates an HHI of 800-1,200, which points to competition that still leaves room for specialty players. - Software differentiation is becoming more important as buyers look for integrated instrument, analytics and service bundles. - Subscription-style procurement is gaining traction because it lowers upfront costs and makes budgets more predictable. - Sustainability is also becoming a buying factor, especially in Europe, where procurement teams face more disclosure pressure.

What's next: - The report expects platform-as-a-service contracts to represent about 30% of total market revenue by 2033. - It says decentralized sequencing and point-of-care testing will keep expanding into clinics, field sites and agricultural testing. - Vendors that can combine instruments, consumables, software and service into one platform are likely to gain share. - Companies named in the report include Thermo Fisher Scientific, Danaher, Agilent Technologies, Merck KGaA, Illumina, Bio-Rad Laboratories, Waters Corporation and Bruker Corporation. - Social links provided in the source include the company's LinkedIn page, Facebook page, YouTube channel and X account.

The bottom line: - The report sees the life science tools market entering a decade of steady growth, powered by public funding, lower sequencing costs and automation that turns labs into data-driven production systems.